How Do German General Practitioners Manage Long-/Post-COVID? A Qualitative Study in Primary Care
Overview
Affiliations
Background: Many patients with ongoing complaints after a SARS-CoV-2 infection are treated in primary care. Existing medical guidelines on how to diagnose and treat Long-/Post-COVID are far from being comprehensive. This study aims to describe how German general practitioners (GPs) deal with this situation, what problems they experience when managing such patients, and how they solve problems associated with the diagnosis and treatment of Long-/Post-COVID.
Methods And Findings: We conducted a qualitative study and interviewed 11 GPs. The most commonly described symptoms were ongoing fatigue, dyspnea, chest tightness and a decrease in physical capacity. The most common way to identify Long-/Post-COVID was by exclusion. Patients suffering from Long-/Post-COVID were generally treated by their GPs and rarely referred. A very common non-pharmacological intervention was to take a wait-and-see approach and grant sick leave. Other non-pharmacological interventions included lifestyle advices, physical exercise, acupuncture and exercises with intense aromas. Pharmacological treatments focused on symptoms, like respiratory symptoms or headaches. Our study's main limitations are the small sample size and therefore limited generalizability of results.
Conclusions: Further research is required to develop and test pharmaceutical and non-pharmaceutical interventions for patients with Long-/Post-COVID. In addition, strategies to prevent the occurrence of Long-/Post-COVID after an acute infection with SARS-CoV-2 have to be developed. The routine collection of data on the diagnosis and management of Long-/Post-COVID may help in the formulation of best practices. It is up to policymakers to facilitate the necessary implementation of effective interventions in order to limit the huge societal consequences of large groups of patients suffering from Long-/Post-COVID.
Brinkmann M, Stolz M, Herr A, Herrmann-Lingen C, Koch I, Muller C PLoS One. 2024; 19(12):e0316335.
PMID: 39739921 PMC: 11687889. DOI: 10.1371/journal.pone.0316335.
Wojczewski S, Mayrhofer M, Szabo N, Rabady S, Hoffmann K BMC Public Health. 2024; 24(1):3078.
PMID: 39511549 PMC: 11542353. DOI: 10.1186/s12889-024-20475-z.
Schulze J, Lind L, Rojas Albert A, Ludtke L, Hensen J, Bergelt C Eur J Gen Pract. 2024; 30(1):2413095.
PMID: 39432372 PMC: 11494714. DOI: 10.1080/13814788.2024.2413095.
An investigation into General Practitioners' experience with Long Covid.
Farrell A, OFlynn J, Jennings A Ir J Med Sci. 2024; 193(6):2869-2873.
PMID: 39162988 PMC: 11666628. DOI: 10.1007/s11845-024-03782-7.
HTRF-based assay for detection of mono-ADP-ribosyl hydrolyzing macrodomains and inhibitor screening.
Ildefeld N, Steinhilber D, Proschak E, Heering J iScience. 2024; 27(7):110333.
PMID: 39055912 PMC: 11269945. DOI: 10.1016/j.isci.2024.110333.